<DOC>
	<DOCNO>NCT01890096</DOCNO>
	<brief_summary>A single high dose rate brachytherapy ( HDR ) treatment combine short course external beam radiotherapy ( EBRT ) highly effective well tolerate treatment men intermediate risk prostate cancer . High cancer control rate also report HDR use , without EBRT . The challenge determine HDR dose use move towards one two fraction several investigator . These schedule report well tolerate short term , little long term data . The objective study investigate HDR monotherapy give either one fraction 19 Gy two fraction 13.5 Gy randomize phase II clinical trial . The primary endpoint patient report toxicity health relate quality life 1 year , efficacy data also analyze . Sample size study 174 patient , expect accrue within 18 month .</brief_summary>
	<brief_title>A Phase II Trial High Dose-Rate Brachytherapy Monotherapy Low Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>histologically confirm diagnosis adenocarcinoma prostate low intermediate risk disease define either Gleason 6 Gleason 7 PSA &lt; 20ng/mL . PSA drawn within 60 day registration prostate volume &lt; 60 cc determine ultrasound , CT MRI willing give inform consent ot participate clinical trial able willing complete Expanded Prostate Index Composite ( EPIC ) questionnaire document nodal distant metastases previous pelvic radiotherapy previous transurethral resection prostate , previous prostatectomy Highly Focused Ultrasound ( HIFU ) use androgen deprivation therapy . Use 5alpha reductase inhibitor permit poor baseline urinary function define radiotherapy eg . connective tissue disease inflammatory bowel disease significant medical comorbidity render patient unsuitable general anaesthetic</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HDR</keyword>
	<keyword>monotherapy</keyword>
	<keyword>low</keyword>
	<keyword>intermediate</keyword>
	<keyword>prostate cancer</keyword>
</DOC>